

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office :- Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

Date: 18th August, 2020

To,
Bombay Stock Exchange Limited
Department of Corporate Services,
25th Floor, P. J. Towers, Dalal Street,
Mumbai-400001

Script ID : 506365

Subject : **SUBMISSION OF COMPLIANCES UNDER SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

Dear Sirs,

We are enclosing herewith Quarterly Compliances pursuant to Securities And Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 for Quarter ended 30th June, 2020 as under -

1.	Regulation 33	Un-audited Quarterly Financial Results for the Quarter ended 30/06/2020 along with Limited Review Report issued by our Auditors, M/s. VMD & Co., Chartered Accountant, Mumbai
2.		Outcome of the Board Meeting Held on 18/08/2020

You are requested to take this on your records.

Thanking You.

Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED

: *Ashok Somani*

ASHOK SOMANI
DIRECTOR
(DIN - 03063364)



Place: Mumbai



VMD & CO.
CHARTERED ACCOUNTANTS

AVMS PREMISES,
4TH FLOOR,
SHREENIWAS HOUSE,
27, H.S. MARG, FORT,
MUMBAI- 400 001
TEL. 2207 7707
FAX 2207 1070
info@vmd.co.in

LIMITED REVIEW REPORT

We have reviewed the accompanying Statement of unaudited financial results of **M/S CHEMO PHARMA LABORATORIES LTD.**, Mumbai for the quarter ended **30th June 2020**. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors / committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagement to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Dated: August 1, 2020
Place: Mumbai
UDIN: 20114222AAAADL8550

For M/s VMD & Co.
Chartered Accountants
FRN: 125002W

CA Amit Ganpule
Partner
MRN: 114222



CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2020

Sr. No.	Particulars	(Rupees in Thousands)			
		Quarter Ended		Year Ended	
		30 th June 2020	31 st March 2020	30 th June 2019	31 st March 2020
		Un-audited	Audited	Un-audited	Audited
I	Revenue from Operations				-
II	Other Income	1,563	2,859	2,831	9,967
III	Total Revenue (I + II)	1,563	2,859	2,831	9,967
IV	Expenses				
	(1) Cost Materials consumed	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-
	(4) Employee Benefits Expenses	245	404	405	1,813
	(5) Depreciation and Amortisation Expenses	-	231	-	231
	(6) Administrative and Other Expenses	431	1,253	923	2,982
	(7) Finance Costs	-	-	-	-
	Total Expenses	676	1,888	1,328	5,026
V	Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)	887	971	1,503	4,941
VI	Exceptional Items	-	-	-	-
VII	Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)	887	971	1,503	4,941
VIII	Extra Ordinary Items	-	-	-	-
IX	Profit/(Loss) before Tax (VII-VIII)	887	971	1,503	4,941
X	Tax Expenses				
	(1) Current Tax	-	760	-	760
	(2) Tax Adjustment Previous Year	56	30	-	30
	(3) Deferred Tax	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)	831	181	1,503	4,151
XII	Profit/(Loss) from discontinuing operations	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-
XV	Profit/(Loss) for the period (XI - XIV)	831	181	1,503	4,151
XVI	Other Comprehensive Income				
	A (i) Itmes that will not be reclassified to profit or loss				
	(ii) Income rax relating to items that will not be reclassified to profit or loss				
	B (i) Itmes that will not be reclassified to profit or loss				
	(ii) Income rax relating to items that will not be reclassified to	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period	831	181	1,503	4,151
XVIII	Earnings per Share :				
	(1) Basic	0.55	0.12	1.00	2.77
	(2) Diluted				

Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Unaudited Financial Results for the Quarter Ended 30.06.2020 have been reviewed by the Audit Committee in their Meeting held on 18.08.2020 and approved by the Board of Directors of its Meeting held on 18.08.2020. The Limited Review Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- The Company is not having any Subsidiary Company.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

For Chemo - Pharma Laboratories Limited

Ashok Somani

Ashok Somani
Director

Place : Mumbai

Date : 18th August, 2020



CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER ENDED 30TH JUNE, 2020

(Rs. in Thousands)

PARTICULARS	STANDLONE	
	UN-AUDITED QUARTER ENDED 30.06.2020	AUDITED YEAR ENDED 31.03.2020
Reconciliation of Profit After Tax as reported earlier:		
Net Profit / (Loss) for the Period (as per AS)	831	4,151
Benefit / (Charge):	-	-
Impact of Deferred Income (Government Grant) Amortized to Income	-	-
Impact of Fair Valuation of Financial Instruments	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-
Impact of Adjustment of Deferred Tax	-	-
Net Profit / (Loss) for the Period (as per AS)	831	4,151

For Chemo - Pharma Laboratories Limited

Place : Mumbai

Date : 18th August, 2020



A handwritten signature in blue ink, appearing to read 'Ashok Somani', written over a horizontal line.

Ashok Somani
Director